In recent years, several key clinical trials have evaluated the use of locoregional transarterial chemotherapy combined with immune checkpoint inhibitors, such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, in liver cancer (98). This evidence concerns the gene CD274 and liver cancer.